704.5000 -19.05 (-2.63%)
NSE Apr 30, 2025 15:31 PM
Volume: 14,765
 

ICICI Securities Limited
Tatva Chintan’s Q3FY23 revenue rose 15% YoY / 34% QoQ to Rs1.2bn as SDA revenue recovered to Rs0.6bn, up 6.4% YoY / 5.7x QoQ. However, non-SDA segments, which hitherto performed well, dipped QoQ. The disappointment come from an 800bps QoQ contraction in gross profit margin to 43.8% due to higher bromine and solvent prices, which have subsequently corrected.
Tatva Chintan Pharma Chem Ltd. has lost -42.63% in the last 1 Year
More from Tatva Chintan Pharma Chem Ltd.
Recommended